Non-Hodgkin's Lymphoma
Approved for the treatment of certain types of indolent and aggressive non-Hodgkin's lymphoma (NHL)
News & Updates
INDICATIONS AND IMPORTANT SAFETY INFORMATION
Chronic Lymphocytic Leukemia (CLL)
RITUXAN® (Rituximab) is indicated in combination with fludarabine and cyclophosphamide (FC chemotherapy) for the treatment of patients with:
- Previously untreated CD20-positive CLL
- Previously treated CD20-positive CLL
Non-Hodgkin’s Lymphoma (NHL)
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Rheumatoid Arthritis (RA)
RITUXAN® (Rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately-to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
People with serious infections should not receive RITUXAN.
Important Safety Information
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. The most common side effects of RITUXAN observed in patients with RA were hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.
Please see Prescribing Information, including Medication Guide.
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.
